Alkermes Targets Bipolar Disorder And Schizophrenia
February 16, 2020 at 11:52 AM EST
We strongly recommend that investors take advantage of the weakness and buy Alkermes, whose treatment of schizophrenia and bipolar disorder has been accepted by the FDA for review.
